TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15220594
Drug: Untreated silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated silicone breast implant rupture
Study: 15220594
Drug: Intact silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact silicone breast implants
Study: 12208405
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg given as twice daily subcutaneous injections)
Study: 2759546
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide‐5‐mononitrate (1-hour post-administration)
Study: 2759546
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide‐5‐mononitrate (7-day administration)
Study: 356719
Drug: Prazosin (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (1-2 mg t.i.d.)
Study: 356719
Drug: Prazosin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin + Hydrochlorothiazide (25 mg daily for 3 weeks)
Study: 356719
Drug: Prazosin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin + Hydrochlorothiazide + Clonidine (low doses for 6 weeks)
Study: 27194393
Drug: Self-regulated modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-regulated modified constraint-induced movement therapy (SR-mCIMT)
Study: 27194393
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy (mCIMT)
Study: 20558084
Drug: Antibody-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-directed therapy (rituximab and intravenous immune globulin (IVIG), or IVIG alone)
Study: 20558084
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for DSA
Study: 10071982
Drug: Capecitabine 1250
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m2 alone (treatment A)
Study: 10071982
Drug: Capecitabine 1250
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m2 followed immediately by Maalox (treatment B)
Study: 10071982
Drug: Capecitabine 1250
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m2 followed 2 hours later by Maalox (treatment C)
Study: 7551385
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen (O2) delivered via nasal cannula at 1 L/min for 4 hours
Study: 7551385
Drug: Room air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room air delivered via nasal cannula at 1 L/min for 4 hours
Study: 1971651
Drug: Single pre-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single pre-operative dose of 1 g ceftazidime (im or iv) 1 hour before surgery
Study: 1971651
Drug: Three peri-operative
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three peri-operative doses of 1 g ceftazidime (im or iv) 1 hour before, and 6 and 12 hours after surgery
Study: 30395857
Drug: Heparin‐based coating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin‐based coating (Carmeda; Medtronic)
Study: 17461296
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg/day in patients with type 2 diabetes
Study: 12064363
Drug: G‐CSF donor
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF donor priming (3 to 4 micro/kg per day for 7 days prior to marrow harvest)
Study: 12064363
Drug: G‐CSF donor
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF donor priming
Study: 9800936
Drug: Antibodies against
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies against copper-oxidised LDL
Study: 9800936
Drug: Antibodies against
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies against MDA-LDL
Study: 23757474
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (CHO) - 800 mL the evening before and 400 mL 2 hours before surgery
Study: 19933596
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) at a target dose of 3.0 g/day
Study: 19933596
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (IVC) at a dose of 0.5‐1.0 g/m(2)/month
Study: 19933596
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) and intravenous cyclophosphamide (IVC)
Study: 16367881
Drug: Glibenclamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide plus metformin
Study: 12679163
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (400 kcal, 15 g protein, 50% of vitamin DRVs) and resistance exercise training
Study: 11147228
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment protocols for remission induction and postremission treatment in ALL
Study: 9377606
Drug: Losartan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (10 to 150 mg once daily, most commonly 50 to 100 mg per day)
Study: 20118146
Drug: Intranasal application
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal application of xenon at a rate of 1.0 litre h(‐1) for 30 min
Study: 15911152
Drug: Flexible-dose pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Flexible-dose pregabalin (150, 300, 450, and 600 mg/day with weekly dose escalation)
Study: 15911152
Drug: Fixed-dose pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-dose pregabalin (300 mg/day for 1 week followed by 600 mg/day for 11 weeks)
Study: 8143220
Drug: Sotalol (173.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (173.3 +/- 59.8 mg/day)
Study: 8143220
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (13 on amiodarone and 3 on beta-blockers)
Study: 27862905
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (INF) 2 μg/kg, maximum 100 μg
Study: 27862905
Drug: Placebo (intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intranasal saline)
Study: 23082885
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ASA therapy)
Study: 16722388
Drug: Yanshu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yanshu injection combining with chemotherapy
Study: 14742225
Drug: Sulfadiazine 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadiazine 2,000 mg administered twice daily (BID)
Study: 14742225
Drug: Sulfadiazine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadiazine 1,000 mg administered four times a day (QID)
Study: 31104505
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg s.c.)
Study: 28481338
Drug: Glutinous brown
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutinous brown rice (GBR) twice a day for 8 weeks
Study: 21887811
Drug: Internet intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Internet intervention (unguided self-help intervention with a depression information website and automated cognitive behavioural therapy)
Study: 19447767
Drug: Glucocorticoid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid therapy (prednisolone or equivalent)
Study: 15384026
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg daily for 4 weeks
Study: 15384026
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg daily for 4 weeks
Study: 15384026
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Candesartan and Enalapril)
Study: 7799392
Drug: Various agents
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various agents (gold injections, D-penicillamine, auranofin, antimalarials, azathioprine, sulfasalazine, methotrexate)
Study: 3259099
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol as a bolus followed by continuous infusion
Study: 29050464
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anti-platelet medication)
Study: 28947466
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG) 1010 colony-forming units twice a day for 5 days
Study: 14733469
Drug: Commercial breath
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial breath analyzer (CBA) measuring volatile sulfur compounds (VSCs) before and after tongue debridement
Study: 3933675
Drug: Olsalazine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine 1 g as a retention enema nightly for two weeks
Study: 3933675
Drug: Oral olsalazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral olsalazine 2 g daily for two weeks
Study: 23698186
Drug: Aliskiren (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150-300 mg/d) and Valsartan (160 mg/d)
Study: 23698186
Drug: Aliskiren (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150-300 mg/d)
Study: 20443741
Drug: Lip muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lip muscle training with an oral screen
Study: 17509852
Drug: Flunisolide (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide (inhaled twice a day for 4 weeks)
Study: 17509852
Drug: Placebo (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inhaled twice a day for 4 weeks)
Study: 15257185
Drug: Candesartan 8-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8-16 mg once daily
Study: 11427285
Drug: 2.5 microg
Normalized name: Digoxin 62.5 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 microg dose of hepatitis B vaccine
Study: 11427285
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg dose of hepatitis B vaccine
Study: 9849709
Drug: Glucocorticoid receptors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid receptors in peripheral mononuclear leukocytes (MNL) of PCOS patients
Study: 9849709
Drug: Glucocorticoid receptors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid receptors in peripheral mononuclear leukocytes (MNL) of healthy women (controls)
Study: 8002670
Drug: Oral potassium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral potassium citrate therapy (600 mEq/day)
Study: 2507028
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment (weight reduction, sodium restriction, decreased alcohol intake)
Study: 2507028
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment (atenolol as first choice)
Study: 12137822
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anesthesia used for groups 2 and 3 (group 4)
Study: 7775629
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms EE plus 3 mg DRSP (group A)
Study: 7775629
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms EE plus 3 mg DRSP (group B)
Study: 7775629
Drug: 15 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 micrograms EE plus 3 mg DRSP (group C)
Study: 7457946
Drug: Fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl citrate (0.0015, 0.003, 0.006 mg/kg)
Study: 7457946
Drug: Morphine chlorhydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine chlorhydrate (0.100, 0.150, 0.200 mg/kg)
Study: 7457946
Drug: Morphine chlorhydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine chlorhydrate
Study: 31051279
Drug: MF59-adjuvanted seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted seasonal trivalent inactivated influenza vaccine (aIIV3)
Study: 31051279
Drug: Non-adjuvanted inactivated
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted inactivated influenza vaccine (IIV3)
Study: 22082794
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all training methods (A)
Study: 15217304
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone (0.1 mg/kg)
Study: 15217304
Drug: Intramuscular oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular oxycodone (0.1 mg/kg)
Study: 15217304
Drug: Buccal oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal oxycodone (0.1 mg/kg)
Study: 15217304
Drug: Gastric oxycodone
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric oxycodone (0.1 mg/kg)
Study: 9611670
Drug: Ketamine (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.12 mg/kg bolus and 0.65 mg/kg/hour)
Study: 7922759
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg of artemisinine daily for 5 days
Study: 7922759
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of mefloquine plus 45 mg of primaquine as a single dose
Study: 29393818
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of 0.75% ropivacaine (group II)
Study: 29393818
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of 0.75% ropivacaine with 100 μg fentanyl (group III)
Study: 28594758
Drug: Early insertion
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early insertion of etonogestrel implant (up to 48 hours postpartum)
Study: 28594758
Drug: Conventional insertion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional insertion of etonogestrel implant (at 6 weeks postpartum)
Study: 28594758
Drug: Early insertion
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early insertion of etonogestrel implant
Study: 28594758
Drug: Conventional insertion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional insertion of etonogestrel implant
Study: 25268386
Drug: Sarpogrelate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate (100 mg bid; total dose of 200 mg)
Study: 25268386
Drug: Sarpogrelate pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate pretreatment (100 mg tid for three days)
Study: 25268386
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg) alone
Study: 24030452
Drug: Nonspecific EAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific EAP treatments, treated once a week for 8 weeks after a 2-week run-in period.
Study: 21935818
Drug: Trigger point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point injection combined with stabilization splint (SS) therapy
Study: 21935818
Drug: Stabilization splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilization splint (SS) therapy
Study: 12228010
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) by needle
Study: 12228010
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) by jet injection (Biojector®)
Study: 12228010
Drug: Intramuscular/intradermally (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular/intradermally (ID) by jet injection
Study: 11910660
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen 0.625 mg, selective estrogen receptor modulator (two doses), or placebo
Study: 6800809
Drug: Antipyrine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyrine (1200 mg daily for 14 days)
Study: 6800809
Drug: Phenobarbital (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (100 mg daily for 14 days)
Study: 6800809
Drug: Rifampicin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (1200 mg daily for 14 days)
Study: 6800809
Drug: Rifampicin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (1200 mg daily for 14 days) with injected 125I-T4
Study: 31483961
Drug: SAGE-217 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217 (30 mg once daily)
Study: 25495357
Drug: Methylphenidate (0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.30 mg/kg)
Study: 25495357
Drug: Methylphenidate (0.60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.60 mg/kg)
Study: 20031860
Drug: Monthly angina
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly angina (score 61 to 99)
Study: 20031860
Drug: Weekly angina
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly angina (score 31 to 60)
Study: 20031860
Drug: Daily angina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily angina (score 0 to 30)
Study: 18187379
Drug: CI >2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI >2.4 L/min per m2
Study: 10695642
Drug: Venlafaxine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine, 300 mg/day
Study: 8251268
Drug: Alfentanil 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 100 micrograms kg‐1 every 5 min to a total dose of 500 micrograms kg‐1
Study: 8251268
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 micrograms kg‐1 every 7 min to a total dose of 50 micrograms kg‐1
Study: 8251268
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg kg‐1 for induction and 0.5 mg kg‐1 every 15 min to a total dose of 3 mg kg‐1
Study: 29226862
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg encapsulated generic losartan once daily for 12 months
Study: 17641562
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine acupuncture
Study: 15508021
Drug: Fentanyl self-administration
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl self-administration (SA) 1.5 mg/70 kg
Study: 15508021
Drug: Fentanyl passive
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl passive administration (PA) 1.5 mg/70 kg
Study: 8543502
Drug: Meropenem 40
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem 40 mg/kg 8-hourly, up to a maximum of 6 g/day (n = 28)
Study: 1674589
Drug: gp160 vaccine
Normalized name: Gp160 Vaccine
DrugBank: VaxSyn (DB17827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp160 vaccine administered on days 0, 30, and 120 or on days 0, 30, 60, 120, 150, and 180
Study: 1674589
Drug: gp160 vaccine
Normalized name: Gp160 Vaccine
DrugBank: VaxSyn (DB17827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp160 vaccine with six injections
Study: 1674589
Drug: gp160 vaccine
Normalized name: Gp160 Vaccine
DrugBank: VaxSyn (DB17827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp160 vaccine with three injections
Study: 23089085
Drug: Acceptance based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance based mirror exposure therapy (A-MET)
Study: 23089085
Drug: Non-directive body
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-directive body image therapy (ND)
Study: 20715729
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg) and tropisetron
Study: 11144934
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily administration of valproate delayed release mini-tablets (VPA mrt.)
Study: 11144934
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily administration of valproate delayed release mini-tablets (VPA mrt.)
Study: 11144934
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with valproate delayed release mini-tablets (VPA mrt.)
Study: 1459268
Drug: Ultrashort regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrashort regimen of gonadotropin-releasing hormone agonist (GnRH-a)
Study: 1459268
Drug: Short regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short regimen of gonadotropin-releasing hormone agonist (GnRH-a)
Study: 6321310
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg X 2/day/7 days)
Study: 6321310
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg X 2/day/7 days)
Study: 31971089
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (4000 IU daily for 4 weeks)
Study: 31495242
Drug: Jessner's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jessner's solution peeling
Study: 31495242
Drug: Dermapen and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermapen and Jessner's solution peeling